Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SPRY domain containing 7 pseudogene 1 (SPRYD7P1) is a non-protein-coding genomic locus annotated as a pseudogene of the SPRYD7 gene. Like other pseudogenes, SPRYD7P1 may act as a non-coding RNA, possibly influencing gene expression by mechanisms such as competing for microRNA binding sites (acting as a “miRNA decoy” or ceRNA), similar to functions documented for other pseudogenes like PTENP1 and KRASP1[1][5][7]. However, there is currently no direct experimental evidence that SPRYD7P1 has a functional impact in cancer or other diseases, nor is it recognized as a therapeutic target or biomarker[3][4]. The related functional gene, SPRYD7, is a protein coding gene associated with cancer progression, particularly in colorectal cancer, where its upregulation correlates with invasion, metastasis, angiogenesis, and poor prognosis[2][4]. This does not extend to the pseudogene SPRYD7P1, which lacks a protein product. Summary: SPRYPD7P1 is a pseudogene, does not produce a functional protein, is not a direct therapeutic target, and current knowledge does not associate it with specific disease or drug response roles[3][1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SPRY domain containing 7 pseudogene 1 (SPRYD7P1).